Tailored Exercise Program Investigated for Mitigating Cardiotoxicity in Breast Cancer Patients
Background
Breast cancer (BC) remains a leading cause of cancer-related deaths among women, with treatments like anthracyclines and anti-human epidermal growth factor receptor-2 (HER2) antibodies often leading to chemotherapy-induced cardiotoxicity. This cardiotoxicity is a significant long-term morbidity, reducing quality of life for survivors. The NLRP3 inflammasome is identified as a crucial molecular link between chemotherapeutic stress and inflammatory cardiomyocyte death. Cardio-oncology rehabilitation programs are being explored to address this critical gap in patient care.
Study Design
This pilot study, registered as NCT04013568, aims to compare the efficacy of a tailored physical exercise program initiated before anticancer treatment versus during anticancer treatment in mitigating cardiotoxicity. The research focuses on breast cancer patients undergoing therapies known to induce cardiovascular side effects. The primary endpoint is to determine if pre-treatment exercise can mitigate the onset or extent of cardiotoxicity more effectively than exercise performed concurrently with chemotherapy. The study design involves longitudinal exercise programming, with patient outcomes assessed over the course of treatment and follow-up.
Why It Matters
If a tailored exercise program, particularly when initiated before anticancer treatment, proves effective in reducing chemotherapy-induced cardiotoxicity, it could fundamentally shift cardio-oncology rehabilitation protocols. This research aims to identify optimal timing for exercise interventions, potentially leading to new standard-of-care guidelines that enhance long-term cardiovascular health and quality of life for breast cancer survivors. Such a finding would empower patients and clinicians with a proactive, non-pharmacological strategy to counteract severe treatment side effects, making cancer therapies more tolerable and sustainable. The study's focus on timing is crucial for developing evidence-based exercise prescriptions that maximize protective benefits against treatment-related damage.
breast-cancer
cardiotoxicity
exercise
chemotherapy
cancer-survivorship
preclinical-animal